Observational studyBMC infectious diseases2025
Lymphocyte-to-procalcitonin ratio: a new predictor of prognosis in COVID-19.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 pneumonia remains a major global health concern and is characterized by a dysregulated inflammatory response. This study aimed to evaluate and compare the lymphocyte-to-procalcitonin ratio (LPCT) with conventional inflammatory markers in predicting clinical outcomes in patients with COVID-19.
methodsThis retrospective observational study was conducted at a tertiary university hospital in Turkey. Adult patients diagnosed with COVID-19 were included between June 1, 2020, and June 1, 2022. Patient demographic and clinical data, including laboratory parameters and comorbidities, were collected from electronic medical records. The primary outcome was in-hospital mortality, while the secondary outcome was the prediction of the requirement for invasive mechanical ventilation.
resultsIn total, 535 patients with COVID-19 infection were included (mean age: 67.10 ± 16.77 years; range: 23-100 years), and 124 (23.2%) in-hospital deaths were observed. Among all laboratory parameters analyzed, the LPCT demonstrated superior predictive performance for mortality compared to other parameters, including LCRP. LPCT exhibited the highest positive predictive value at 51.1%. A decrease in LPCT [HR: 4.05 (95% CI: 2.41-6.81)], positive CT findings [HR: 2.54 (95% CI: 1.34-4.81)], and elevated D-Dimer [HR: 1.86 (95% CI: 1.16-2.99)] were identified as independent predictors of in-hospital mortality. Moreover, decreased LPCT was strongly associated with an increased need for mechanical ventilation [OR: 7.53 (95% CI: 3.84-14.78), p < 0.001].
conclusionsThis study demonstrated the prognostic value of the lymphocyte-to-procalcitonin ratio (LPCT) in predicting in-hospital mortality and the need for mechanical ventilation among COVID-19 patients. To our knowledge, this is the first study to evaluate LPCT as a prognostic biomarker in COVID-19. Future studies should explore the effectiveness of LPCT in other viral infections, particularly in older populations where the sensitivity of CRP may be reduced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.